Publications by authors named "Erik Verner"

Claim this Profile
D
Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib).
Timothy D Owens, Ken A Brameld, Erik J Verner, Tony Ton, Xiaoyan Li

J Med Chem· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance.
Eleni Venetsanakos, Ken A Brameld, Vernon T Phan, Erik Verner, Timothy D Owens

Mol Cancer Ther· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors.
Ken A Brameld, Timothy D Owens, Erik Verner, Eleni Venetsanakos, J Michael Bradshaw

J Med Chem· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolonged and tunable residence time using reversible covalent kinase inhibitors.
J Michael Bradshaw, Jesse M McFarland, Ville O Paavilainen, Angelina Bisconte, Danny Tam, Erik Verner

Nat Chem Biol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694.
Yiming Zhong, Shuai Dong, Ethan Strattan, Li Ren, Jonathan P Butchar, Erik Verner

J Biol Chem· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.
Lee A Honigberg, Ashley M Smith, Mint Sirisawad, Erik Verner, David Loury

Proc Natl Acad Sci U S A· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isoform-specific histone deacetylase inhibitors: the next step?
Sriram Balasubramanian, Erik Verner, Joseph J Buggy

Cancer Lett· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo.
Z Alexander Cao, Kathryn E Bass, Sriram Balasubramanian, Liang Liu, Brian Schultz, Erik Verner

Mol Cancer Ther· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo.
Joseph J Buggy, Z Alexander Cao, Kathryn E Bass, Erik Verner, Sriram Balasubramanian

Mol Cancer Ther· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generation of potent coagulation protease inhibitors utilizing zinc-mediated chelation.
Wendy B Young, Paul Sprengeler, William D Shrader, Yong Li, Roopa Rai, Erik Verner

Bioorg Med Chem Lett· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA).
Bradley A Katz, Christine Luong, Joseph D Ho, John R Somoza, Erik Gjerstad, Erik Verner

J Mol Biol· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases.
John R Somoza, Robert J Skene, Bradley A Katz, Clifford Mol, Joseph D Ho, Erik Verner

Structure· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors.
Bradley A Katz, Kyle Elrod, Erik Verner, Richard L Mackman, Christine Luong

J Mol Biol· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-(2-Hydroxy-3-alkoxyphenyl)-1H-benzimidazole-5-carboxamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors.
Richard L Mackman, Hon C Hui, J Guy Breitenbucher, Bradley A Katz, Christine Luong, Erik Verner

Bioorg Med Chem Lett· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis